JP6408092B2 - 糞便微生物叢を含む組成物 - Google Patents

糞便微生物叢を含む組成物 Download PDF

Info

Publication number
JP6408092B2
JP6408092B2 JP2017163690A JP2017163690A JP6408092B2 JP 6408092 B2 JP6408092 B2 JP 6408092B2 JP 2017163690 A JP2017163690 A JP 2017163690A JP 2017163690 A JP2017163690 A JP 2017163690A JP 6408092 B2 JP6408092 B2 JP 6408092B2
Authority
JP
Japan
Prior art keywords
fmt
case
gvhd
composition
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017163690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018035153A5 (cg-RX-API-DMAC7.html
JP2018035153A (ja
Inventor
和彦 垣花
和彦 垣花
正平 服部
正平 服部
賢也 本田
賢也 本田
博嘉 西川
博嘉 西川
英利 森田
英利 森田
梢 竹下
梢 竹下
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
University of Tokyo NUC
Tokyo Metropolitan Government
Original Assignee
Keio University
University of Tokyo NUC
Tokyo Metropolitan Government
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University, University of Tokyo NUC, Tokyo Metropolitan Government filed Critical Keio University
Publication of JP2018035153A publication Critical patent/JP2018035153A/ja
Publication of JP2018035153A5 publication Critical patent/JP2018035153A5/ja
Application granted granted Critical
Publication of JP6408092B2 publication Critical patent/JP6408092B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2017163690A 2016-08-29 2017-08-28 糞便微生物叢を含む組成物 Active JP6408092B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016166656 2016-08-29
JP2016166656 2016-08-29

Publications (3)

Publication Number Publication Date
JP2018035153A JP2018035153A (ja) 2018-03-08
JP2018035153A5 JP2018035153A5 (cg-RX-API-DMAC7.html) 2018-05-17
JP6408092B2 true JP6408092B2 (ja) 2018-10-17

Family

ID=61565352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017163690A Active JP6408092B2 (ja) 2016-08-29 2017-08-28 糞便微生物叢を含む組成物

Country Status (2)

Country Link
US (2) US20180185421A1 (cg-RX-API-DMAC7.html)
JP (1) JP6408092B2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3062063B1 (fr) * 2017-01-26 2019-04-19 Centre National De La Recherche Scientifique Microbiote fecal pour traiter des patients subissant une greffe de cellules souches hematopoietiques
JP2021526526A (ja) * 2018-06-14 2021-10-07 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
MX2018010105A (es) * 2018-08-21 2020-02-24 Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C Sistema de estabilización de microbiota intestinal humana.
CN113728088B (zh) 2018-09-13 2025-02-14 未知君有限责任公司 治疗胃肠障碍和炎性障碍的方法和组合物
CA3136833A1 (en) * 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Beta-lactamase compositions for treatment of graft versus host disease
WO2021106952A1 (ja) * 2019-11-26 2021-06-03 東京都 移植片対宿主病に対する予防又は治療用組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364586A1 (en) * 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
WO2005032589A1 (ja) * 2003-10-02 2005-04-14 Japan Science And Technology Agency Ｇｖｈｄの予防及び治療
WO2011151941A1 (ja) * 2010-06-04 2011-12-08 国立大学法人東京大学 制御性ｔ細胞の増殖または集積を誘導する作用を有する組成物
CN104160014A (zh) * 2011-12-01 2014-11-19 国立大学法人东京大学 诱导调节性t细胞的增殖或积累的人源细菌
WO2014078911A1 (en) * 2012-11-26 2014-05-30 Borody Thomas J Compositions for the restoration of a fecal microbiota and methods for making and using them
WO2014152338A1 (en) * 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
US10076546B2 (en) * 2013-03-15 2018-09-18 Seres Therapeutics, Inc. Network-based microbial compositions and methods
CN111265531B (zh) * 2013-10-25 2023-11-10 药品循环有限责任公司 治疗和预防移植物抗宿主病的方法
AU2014344795B2 (en) * 2013-11-04 2016-05-26 East Health Metropolitan Service Cell culture method
PL3223835T3 (pl) * 2014-11-25 2025-03-31 Memorial Sloan-Kettering Cancer Center Mikrobiota jelitowa i gvhd
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome

Also Published As

Publication number Publication date
JP2018035153A (ja) 2018-03-08
US20200038459A1 (en) 2020-02-06
US20180185421A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
JP6408092B2 (ja) 糞便微生物叢を含む組成物
Grégoire et al. mesenchymal stromal cell therapy for inflammatory bowel diseases
Frickhofen et al. Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporine
US20240197848A1 (en) Therapeutic vaccine for treatment of diabetes type 1 in children, application of the cell sorter and the method of multiplying treg cells to produce therapeutic vaccine for treatment of diabetes type 1
Scandling et al. Macrochimerism and clinical transplant tolerance
CA2929333C (en) Cell culture method comprising transfer to serum medium having the same species origin as the cells being cultured
Morath et al. Phase I trial of donor-derived modified immune cell infusion in kidney transplantation
KR20210033984A (ko) 치료-유발된 염증 감소에 사용하기 위한 분변 미생물총 조성물
KR20180041229A (ko) 줄기 세포 이식을 위한 방법
WO2021106952A1 (ja) 移植片対宿主病に対する予防又は治療用組成物
Fujii et al. The rapid efficacy of abatacept in a patient with rheumatoid vasculitis
ES2365463T3 (es) Fotoféresis extracorpórea en combinación con tratamiento anti-tnf.
EP2758054B1 (en) Beta-lactam compounds for treating diabetes
Perrot et al. Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (IRd) combination followed by extended IRd consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐03
Luo et al. Allogeneic hematopoietic stem cell transplantation following donor CIK cell infusion: A phase I study in patients with relapsed/refractory hematologic malignancies
WO2022161484A1 (en) Methods of treating chronic active antibody-mediated rejection using btk inhibitors
WO2006109300A1 (en) Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients
Chaturvedi et al. Infection‐Associated Immune Reconstitution Inflammatory Syndrome in Hematopoietic Cell Transplantation
Kaufman et al. Induction of immune tolerance in living related human leukocyte antigen–matched kidney transplantation: A phase 3 randomized clinical trial
US20230043598A1 (en) Capsule comprising a faecal composition
US20230201256A1 (en) Calcineurin inhibitor to improve cd3+cell survival to thereby facilitate engraftment of donor cd34+ cells in a recipient
ES2973943T3 (es) Terapia para células inmunitarias modificadas (MIC) para la inmunosupresión específica en trasplantes
US20100129329A1 (en) METHODS FOR USING ALDHbr CELLS TO SUPPLEMENT STEM CELL TRANSPLANTATION
Antin Approaches to graft‐vs‐host disease
Wong et al. Hematopoietic stem cell transplantation as rescue therapy for refractory autoimmune retinopathy: a case report

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180327

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20180327

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180831

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180911

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180919

R150 Certificate of patent or registration of utility model

Ref document number: 6408092

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250